Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
6(85.7%)
Phase 4
1(14.3%)
7Total
Phase 2(6)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03910803Phase 2Unknown

Treatment of Moderate Hidradenitis Suppurativa

Role: lead

NCT02695212Phase 2Completed

Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

Role: lead

NCT01132989Phase 2Unknown

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

Role: lead

NCT01132235Phase 4Unknown

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

Role: lead

NCT00797784Phase 2Unknown

The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus

Role: lead

NCT00827996Phase 2Completed

To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa

Role: lead

NCT00795574Phase 2Completed

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

Role: lead

All 7 trials loaded